Geron And University Of California, Irvine Awarded BioSTAR Grant

Geron Corporation has announced the renewal of a matching grant from the University of California BioSTAR Project to support continued research on the use of human embryonic stem cells (hESCs) to derive oligodendrocytes for the treatment of spinal cord and related central nervous system (CNS) injuries. The work, originally initiated in August 2001 with Geron Read more about Geron And University Of California, Irvine Awarded BioSTAR Grant[…]

eXegenics And Innovative Drug Delivery Systems To Merge

eXegenics Inc. Innovative Drug Delivery Systems, Inc. (IDDS) have signed a definitive merger agreement. Mark C. Rogers, M.D., currently Chairman and CEO of IDDS, will be named Executive Chairman of the combined company and Dr. Ronald L. Goode, Ph.D., currently eXegenics’ President and CEO, will continue as President and CEO. “The merger of eXegenics and Read more about eXegenics And Innovative Drug Delivery Systems To Merge[…]

Transmolecular Awarded Phase II Sbir Grant

TransMolecular, Inc. has received a Phase II Small Business Innovation Research (SBIR) grant to discover and develop pharmaceutical alternatives for treating neuropathic pain. The grant is worth approximately $760,000 over the next two years. “Neuropathic or chronic pain represents an underserved medical need. Ion channels have played an important part in the development of many Read more about Transmolecular Awarded Phase II Sbir Grant[…]

Neurochem And SELECT Therapeutics Collaborate On Alzheimer’s Vaccine

Neurochem, Inc. and SELECT Therapeutics, Inc. have announced the initiation of a collaboration program to advance a novel vaccine intended to prevent the development and the progression of Alzheimer’s Disease. The vaccine will target the prevention of an accumulation of beta- amyloid, a protein that constitutes a major part of plaques in the brain of Read more about Neurochem And SELECT Therapeutics Collaborate On Alzheimer’s Vaccine[…]

Johnson &Johnson’s Epilepsy Drug Leads To Weight Loss

Johnson & Johnson have announced that obese patients lost over 11 percent of their body weight one year after being treated with the company’s anti-epilepsy drug Topamax.The firm is encouraged to continue developing the medicine as a weight-loss medicine.Topamax is currently approved only for treatment of epilepsy, but the New Brunswick, N.J.-based firm is also Read more about Johnson &Johnson’s Epilepsy Drug Leads To Weight Loss[…]

IVAX Acquires Drug In Advanced Clinical Development

IVAX Corporation has entered into an exclusive agreement with Eli Lilly and Company to develop and market the AMPA receptor antagonist, talampanel, worldwide. Phase II clinical trials with talampanel in patients with severe epilepsy not responsive to other drugs have shown positive results and phase III trials in epilepsy will be done to confirm and Read more about IVAX Acquires Drug In Advanced Clinical Development[…]

FDA Grants Fast Track Designation For Secretin

Repligen Corporation announced that the U.S. FDA has granted Fast Track designation for secretin for the treatment of pediatric autism. “We are very pleased that the FDA has designated this program for Fast Track status,” stated Walter C. Herlihy, President and CEO of Repligen Corporation. “We believe that this action affirms a heightened awareness to Read more about FDA Grants Fast Track Designation For Secretin[…]

New Treatment Option Approved For Lennox-Gastaut Syndrome

The U.S. FDA has approved Topamax (topiramate) tablets and sprinkle capsules as an adjunctive (add-on) treatment for adults and children (age 2-16) suffering from seizures associated with Lennox-Gastaut Syndrome (LGS) is one of the most severe forms of epilepsy. Individuals who suffer from this illness experience dozens of seizures a day, many of which are Read more about New Treatment Option Approved For Lennox-Gastaut Syndrome[…]

Dr. Reddy’s And PRI Sign Co-Marketing Agreement

Pharmaceutical Resources, Inc. (PRI) has entered into a broad-based co-marketing and development agreement with Dr. Reddy’s Laboratories (Reddy).The agreement covers fourteen drugs to be marketed through PRI’s primary operating subsidiary, Par Pharmaceutical, Inc., (Par). Abbreviated new drug applications for six of the drugs have been filed with the FDA and are pending approval. Through PRI’s Read more about Dr. Reddy’s And PRI Sign Co-Marketing Agreement[…]

(R)-Fluoxetine License Agreement To Become Effective

Sepracor Inc. has announced that the Federal Trade Commission (FTC) has closed its investigation, under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act, of the license agreement that allows Eli Lilly and Company to exclusively develop and globally commercialize (R) – fluoxetine. (R)-Fluoxetine, a new chemical entity, is a modified form of an active ingredient found in Read more about (R)-Fluoxetine License Agreement To Become Effective[…]